Europeiska unionen - svenska - EMA (European Medicines Agency)

mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - diabetes mellitus, typ 2 - läkemedel som används vid diabetes - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. - , trippel kombinationsterapi) som ett komplement till kost och motion hos patienter bristfälligt kontrollerad på deras maximal tolererad dos av metformin och en sulphonylurea. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Europeiska unionen - svenska - EMA (European Medicines Agency)

accord healthcare s.l.u. - metformin hydrochloride, vildagliptin - diabetes mellitus, typ 2 - läkemedel som används vid diabetes - vildagliptin/metformin hydrochloride accord is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:- in patients who are inadequately controlled with metformin hydrochloride alone. - in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. - in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 och 5. 1 för tillgänglig data på olika kombinationer).

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

abacus medicine a/s - ondansetronhydrokloriddihydrat - filmdragerad tablett - 8 mg - laktos (vattenfri) hjälpämne; ondansetronhydrokloriddihydrat 9,972 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

abacus medicine a/s - ondansetronhydrokloriddihydrat - filmdragerad tablett - 4 mg - laktos (vattenfri) hjälpämne; ondansetronhydrokloriddihydrat 4,986 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

abacus medicine a/s - ziprasidonhydroklorid (vattenfri) - kapsel, hård - 40 mg - ziprasidonhydroklorid (vattenfri) 43,44 mg aktiv substans

Europeiska unionen - svenska - EMA (European Medicines Agency)

accord healthcare s.l.u. - metformin hydrochloride, sitagliptin hydrochloride monohydrate - diabetes mellitus, typ 2 - läkemedel som används vid diabetes - for adult patients with type 2 diabetes mellitus:it is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. it is indicated in combination with a sulphonylurea (i. - , trippel kombinationsterapi) som ett komplement till kost och motion hos patienter bristfälligt kontrollerad på deras maximal tolererad dos av metformin och en sulphonylurea. it is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. it is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

abacus medicine a/s - midodrinhydroklorid - tablett - 2,5 mg - midodrinhydroklorid 2,5 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

abacus medicine a/s - valaciklovirhydroklorid (vattenfri) - filmdragerad tablett - 250 mg - valaciklovirhydroklorid (vattenfri) 278,138 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

abacus medicine a/s - betahistindihydroklorid - tablett - 8 mg - mannitol hjälpämne; betahistindihydroklorid 8 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

abacus medicine a/s - betahistindihydroklorid - tablett - 16 mg - mannitol hjälpämne; betahistindihydroklorid 16 mg aktiv substans